Nephros Initiates Supplemental European Trials for OLpur MD190

Nephros announced it is initiating supplemental clinical trials across five nations in Europe to demonstrate therapy effectiveness and treatment cost savings achieved through the use of its OLpur MD190 filter product in providing therapy for chronic end stage renal disease. Trials are being initiated in the UK, France, Germany, Italy and Sweden. Nephros will conduct three separate trials with durations ranging from 6 to 12 months.

()a href="http://www.medadnews.com/News/Index.cfm?articleid=243511" target="_blank">PharmaLive